Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation(367 views) Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2008 Mar; 52(1): 2-8.
Fondazione SDN, via Emanuele Gianturco 113, 80143 Napoli, Italy
Department of Biomorphological and Functional Sciences, Federico II University, Naples, Italy
Institute of Biostructures and Bioimages, National Council of Research, Naples, Italy
References: Differentiated thyroid carcinoma: treatment and follow-up. Guidelines SIE-AIMN-AIFM
2004Pace, L., Klain, M., Albanese, C., Salvatore, B., Storto, G., Soricelli, A., Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment (2006) Eur J Nucl Med Mol maging, 33, pp. 179-18
Filesi, M., Signore, A., Ventroni, G., Melacrinis, F.F., Ronga, G., Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases (1998) J Nucl Med, 39, pp. 1542-1546
Stokkel, M.P.M., Duchateau, C.S.J., Dragoiescu, C., The value of FDG-PET in the follow-up of differentiated thyroid cancer: A review of the literature. Q (2006) J Nucl Med Mol Imaging, 50, pp. 78-87
Bomanji, J.B., Costa, D.C., Ell, P.J., Clinical role of posiron emission tomography in oncology (2001) Lancet Oncol, 2, pp. 157-164
Schoder, H., Yeung, H.W.D., Positron emission imaging of head and neck cancer, including thyroid carcinoma (2004) Semin Nucl Med, 34, pp. 180-197
Feine U. Fluor 18-deoxyglucose positron emission tomograph in differentiated thyroid cancer. Eur J Endocrinol 1998
138:4927Grunwald, F., Kalicke, T., Feine, U., Lietzenmayer, R., Scheidhauer, K., Diedein, M., Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study (1999) Eur J Nucl Med, 26, pp. 1547-1552
Wang, W., Larson, S.M., Fazzari, M., Tickoo, S.K., Kolbert, K., Sgouros, G., Prognostic value of 18-F-fluorodeoxyglucose positron emission tomograhy scanning in patients with thyroid cancer (2000) J Clin Endocrinol Metab, 85, pp. 1107-1113
Alnafisi, N.S., Driedger, A.A., Coates, G., Moote, D.J., Raphael, S.J., FDG PET of recurrent or metastatic I-negative papillary thyroid carcinoma (2000) Nucl Med, 41, pp. 1010-1015
Palmedo, H., Bucerius, J., Joe, A., Strunk, H., Hortling, N., Meyka, S., Integrated PET/CT in differentiated thyroid cancer: Diagnostic accuracy and impact on patient management (2006) J Nucl Med, 47, pp. 616-624
Schlumberger, M., Arcangioli, O., Piekarski, J.D., Tubiana, M., Parmentier, C., Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-ray (1988) J Nucl Med, 29, pp. 1790-1794
Pacini, F., Agate, L., Elisei, R., Capezzone, M., Ceccarelli, C., Lippi, F., Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131-I whole body scan: Comparison of patients treated with high 131-I activities versus untreated patients (2001) J Clin Endocrinol Metab, 86, pp. 4092-4097
Lind, P., I-131 whole body scintigraphy in thyroid cancer patients (1999) Q J Nucl Med, 43, pp. 188-194
Lind, P., Should high hTg levels in the absence of iodine uptake be treated? (2003) Eur J Nucl Med, 30, pp. 157-160
Schlumberger, M., Tubiana, M., De Vathaire, F., Hill, C., Gardet, P., Travagli, J.P., Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma (1986) J Clin Endocrinol Metab, 63, pp. 960-967
Nemec, J., Rohling, S., Zamrazil, V., Pohunkova, D., Comparison of the distribution of diagnostic and thyroablative 1-131 in the evaluation of differentiated thyroid cancer (1979) J Nucl Med, 20, pp. 92-97
Pacini, F., Lari, R., Mazzeo, S., Grasso, L., Taddei, D., Pinchera, A., Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer (1985) Clin Endocrinol, 23, pp. 405-411
Sherman, S.I., Tielens, E.T., Sostre, S., Wharam Jr, M.D., Ladenson, P.W., Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma (1994) J Clin Endocrinol Metab, 78, pp. 629-634
Reynolds, J.C., Percent 131-I uptake and post-therapy 131-I scans: Their role in the management of thyroid cancer (1997) Thyroid, 7, pp. 281-284
Venkataraman, G.M., Yatin, M., Ain, K.B., Cloning of the human sodium-iodine symporter promoter and characterization in a different human thyroid cell line (1998) Thyroid, 8, pp. 63-69
Lazar, V., Bidart, J.M., Caillou, B., Mahe, C., Lacroix, L., Filetti, S., Expression of the Na+/I- symporter gene in human thyroid tumors: A comparison study with other thyroid-specific genes (1999) J Clin Endocrinol Metab, 84, pp. 3228-3234
Arturi, F., Russo, D., Schlumberger, M., du Villard, J.A., Caillou, B., Vigneri, P., Iodide symporter gene expression in human thyroid tumors (1998) J Clin Endocrinol Metab, 83, pp. 2493-2496
Helal, B.O., Merlet, P., Toubert, M.E., Franc, B., Schvartz, C., Gauthier-Koelesnikov, H., Clinical impact of 18F-FDG in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy (2001) J Nucl Med, 42, pp. 1464-1469
Dietlein, M., Scheidhauer, K., Voth, E., Theissen, P., Schicha, H., Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer (1997) Eur J Nucl Med, 24, pp. 1342-1348
Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD et al. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole-body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999
84:2291-302Lind, P., Kohlfurst, S., Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer (2006) Semin Nucl Med, 36, pp. 194-205
Schluter, B., Bohuslavizki, K.H., Beyer, W., Plotkin, M., Buchert, R., Clausen, M., Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan (2001) J Nucl Med, 42, pp. 71-76
Iagaru, A., Masamed, R., Singer, P.A., Conti, P.S., 2-deoxy-2[18F]fluoro-D-glucose-positron emission tomography/ computer tomography diagnosis of patients with recurrent papillary thyroid cancer (2006) Mol Imaging Biol, 8, pp. 309-314
Robbins, R.J., Wan, Q., Grewal, R.K., Reibke, R., Gonen, M., Strauss, H.W., Real time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning (2006) J Clin Endocrinol Metab, 91, pp. 498-505
Chin, B.B., Patel, P., Cohade, C., Ewertz, M., Wahl, R., Ladenson, P., Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma (2004) J Clin Endocrinol Metab, 89, pp. 91-95
Moog, F., Linke, R., Manthey, N., Tiling, R., Knesewitsch, P., Tatsch, K., Influence of thyroid-stimulating hormone levels on uptake of fdg in recurrent and metastatic differentiated thyroid carcinoma (2000) J Nucl Med, 41, pp. 1989-1995
Petrich, T., Borner, A.R., Otto, D., Hofmann, M., Knapp, W.H., Influence of rhTSH on [18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma (2002) Eur J Nucl Med Mol Imaging, 29, pp. 641-647
Deichen, J.T., Schmidt, C., Prante, O., Maschauer, S., Papadopoulos, T., Kuwert, T., Influence of TSH on uptake of [18F] fluorodeoxyglucose in human thyroid cells in vitro (2004) Eur J Nucl Med Mol Imaging, 31, pp. 507-512
Blaser, D., Maschauer, S., Kuwert, T., Prante, O., In vitro studies on the signal transduction of thyroidal uptake of 18F-FDG and 131I-Iodide (2006) J Nucl Med, 47, pp. 1382-1388
Sisson, J.C., Ackermann, R.J., Meyer, M.A., Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy (1993) J Clin Endocrinol Metab, 77, pp. 1090-1094
Lietzenmayer, R., Muller-Berg, M., Thelen, M.H., Dohmen, B.M., Muller-Schauenburg, W., Bares, R., Follow-up after radioiodine treatment of differentiated thyroid cancer (1998) Nuklearmedizin, 37, pp. A23
Schonberger, J., Ruschoff, J., Grimm, D., Marienhagen, J., Rummele, P., Meyringer, R., Glucose transporter 1 gene expression is related to thyroid neoplasm with an unforable prognosis: An immuno-histochemical study (2002) Thyroid, 12, pp. 747-754
Nahas, Z., Goldenberg, D., Fakhry, C., Ewertz, M., Zeiger, M., Ladenson, P.W., The role of positron emission tomograph/computed tomography in the management of recurrent papillary thyroid carcinoma (2005) Laryngoscope, 115, pp. 237-243
Chung, J.K., So, Y., Lee, J.S., Choi, C.W., Lim, S.M., Lee, D.S., Value of EDG PET in papillary thyroid carcinoma with negative 131I whole-body scan (1999) J Nucl Med, 40, pp. 986-992
Stokkel, M. P. M., Duchateau, C. S. J., Dragoiescu, C., The value of FDG-PET in the follow-up of differentiated thyroid cancer: A review of the literature. Q (2006) J Nucl Med Mol Imaging, 50, pp. 78-87
Bomanji, J. B., Costa, D. C., Ell, P. J., Clinical role of posiron emission tomography in oncology (2001) Lancet Oncol, 2, pp. 157-164
138: 4927Grunwald, F., Kalicke, T., Feine, U., Lietzenmayer, R., Scheidhauer, K., Diedein, M., Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study (1999) Eur J Nucl Med, 26, pp. 1547-1552
Alnafisi, N. S., Driedger, A. A., Coates, G., Moote, D. J., Raphael, S. J., FDG PET of recurrent or metastatic I-negative papillary thyroid carcinoma (2000) Nucl Med, 41, pp. 1010-1015
Sherman, S. I., Tielens, E. T., Sostre, S., Wharam Jr, M. D., Ladenson, P. W., Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma (1994) J Clin Endocrinol Metab, 78, pp. 629-634
Reynolds, J. C., Percent 131-I uptake and post-therapy 131-I scans: Their role in the management of thyroid cancer (1997) Thyroid, 7, pp. 281-284
Venkataraman, G. M., Yatin, M., Ain, K. B., Cloning of the human sodium-iodine symporter promoter and characterization in a different human thyroid cell line (1998) Thyroid, 8, pp. 63-69
Helal, B. O., Merlet, P., Toubert, M. E., Franc, B., Schvartz, C., Gauthier-Koelesnikov, H., Clinical impact of 18F-FDG in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy (2001) J Nucl Med, 42, pp. 1464-1469
84: 2291-302Lind, P., Kohlfurst, S., Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer (2006) Semin Nucl Med, 36, pp. 194-205
Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gonen, M., Strauss, H. W., Real time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning (2006) J Clin Endocrinol Metab, 91, pp. 498-505
Chin, B. B., Patel, P., Cohade, C., Ewertz, M., Wahl, R., Ladenson, P., Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma (2004) J Clin Endocrinol Metab, 89, pp. 91-95
Deichen, J. T., Schmidt, C., Prante, O., Maschauer, S., Papadopoulos, T., Kuwert, T., Influence of TSH on uptake of [18F] fluorodeoxyglucose in human thyroid cells in vitro (2004) Eur J Nucl Med Mol Imaging, 31, pp. 507-512
Sisson, J. C., Ackermann, R. J., Meyer, M. A., Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy (1993) J Clin Endocrinol Metab, 77, pp. 1090-1094
Chung, J. K., So, Y., Lee, J. S., Choi, C. W., Lim, S. M., Lee, D. S., Value of EDG PET in papillary thyroid carcinoma with negative 131I whole-body scan (1999) J Nucl Med, 40, pp. 986-992
Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation
Aim. The aim of this study was to evaluate the role of 18F fluorodeoxyglucose-positron emission tomography (FDG-PET), differentiated thyroid cancer and thyroglobulin in patients with differentiated thyroid carcinoma (DTC) treated with therapeutic 131I because of elevated thyroglobulin (Tg) levels during follow-up. The results of FDG-PET/CT were compared with post-therapy 131I whole-body scan (131I-t-WBS) and Tg at short-term follow-up. Methods. Forty-five patients with DTC underwent a new therapeutic 131I administration based upon Tg values >1.5 ng/mL. All patients underwent 131I-t-WBS 5-7 days after 131I therapy. A few days before 131I administration, a FDG-PET/CT scan was performed in all patients. FDG-PET/CT was considered positive (PET+) when at least one abnormal focus of FDG uptake was found; likewise, 131I-t-WBS was considered positive (WBS+) when at least one abnormal focus of uptake was found. Assessment of short-term response to radioiodine was performed by measuring Tg values. Results. FDG-PET/CT was positive in 32 patients, 23 of which had a positive 131I-t-WBS, and negative in 13, 8 of which had a negative 131I-t-WBS. Overall agreement was 69%. Tg values were significantly higher in FDG-PET/CT positive (502 ± 1 027 ng/mL) than in FDG-PET/CT negative patients (57 ± 94 ng/mL). A significant difference emerged between 131I-t-WBS positive (561 ±1 086 ng/mL) and 131I-t-WBS negative (65 ± 120 ng/mL) findings. in these 45 patients, Tg normalized in 36%, was reduced by at least 50% in 24%, and remained unchanged in the remaining 40%. overall, at short-term follow-up, Tg values normalized in 77% of the 13 patients with negative FDG-PET/CT and in 19% of the 32 patients with positive FDG-PET/CT. Conclusion. FDG-PET/CT is a powerful and useful tool for assessing patients with DTC. It can provide additional information in those patients with high Tg at follow-up and eligible for 131I therapy. A negative FDG-PET/CT could also represent a prognostic tool combined with serum Tg testing at short term follow-up.
Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(496 views) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 ViewExport to BibTeXExport to EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(819 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote
Ntziachristos V, Cuénod CA, Fournier L, Balvay D, Pradel C, Siauve N, Clement O, Jouannot E, Lucidarme O, Vecchio SD, Salvatore M, Law B, Tung C-H, Jain RK, Fukumura D, Munn LL, Brown EB, Schellenberger E, Montet X, Weissleder R, Clerck ND, Postnov A * Tumor Imaging(350 views) Textbook Of In Vivo Imaging In Vertebrates (ISSN: 9780-4700), 2007 Jul 16; 1: 277-309. Impact Factor:1.148 ViewExport to BibTeXExport to EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(694 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote